Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 250 IN PLASTIC CONTAINER versus RENOVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 250 IN PLASTIC CONTAINER versus RENOVIST.
IOPAMIDOL-250 IN PLASTIC CONTAINER vs RENOVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiographic contrast medium that attenuates X-rays and provides radiopacity in vascular and body cavities. It does not undergo significant pharmacological activity.
RENOVIST is a radiocontrast agent that enhances imaging by attenuating X-rays due to its iodine content. It acts by increasing the density of blood vessels and tissues, improving contrast in radiographic studies.
250 mg iodine/mL; 1.5 mL/kg (up to 100 mL) IV bolus or infusion for CT imaging.
0.5-1 mg/kg intravenously daily
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 30+ hours in severe impairment), dictating contrast dosing intervals
Terminal half-life: 12 hours; in renal impairment (CrCl <30 mL/min) prolonged to 24-36 hours; dose adjustment required
Renal: 95% unchanged via glomerular filtration; biliary/fecal: <5%
Renal: 70% as unchanged drug; fecal: 20% as metabolites; biliary: 10%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent